Abstract Types

CRA
Clinical Review Abstract

LBA
Late-Breaking Abstract

TPS
Trials in Progress Abstract

e
Abstracts selected for publication but not presentation at the Annual Meeting

^
Abstracts granted an exception in accordance with ASCO's Conflict of Interest Policy



Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).

Sub-category:
CNS Tumors

Category:
Central Nervous System Tumors

Meeting:
2013 ASCO Annual Meeting

Abstract No:
LBA2010

Citation:
J Clin Oncol 31, 2013 (suppl; abstr LBA2010)

Attend this session at the
ASCO Annual Meeting!

Session: Predictive Molecular Biomarkers: Enriching Clinical Trial Populations for Gliomas

Type: Clinical Science Symposium

Time: Sunday June 2, 8:00 AM to 9:30 AM

Location: E253

Personalize your Annual Meeting experience with a suggested or customized itinerary!

Author(s): Erik P. Sulman, Minhee Won, Deborah T. Blumenthal, Michael A. Vogelbaum, Howard Colman, Robert B. Jenkins, Arnab Chakravarti, Robert Jeraj, Paul D. Brown, Kurt A. Jaeckle, David Schiff, James Dignam, James Norman Atkins, David Brachman, Maria Werner-Wasik, Ritsuko Komaki, Mark R. Gilbert, Minesh P. Mehta, Kenneth D. Aldape; The University of Texas MD Anderson Cancer Center, Houston, TX; Radiation Therapy Oncology Group, Philadelphia, PA; Tel Aviv Sourasky Medical Center, Tel Aviv, Israel; Cleveland Clinic Foundation, Cleveland, OH; University of Utah, Huntsman Cancer Institute, Salt Lake City, UT; Mayo Clinic, Rochester, MN; Arthur G. James Cancer Center, The Ohio State University, Columbus, OH; Department of Medical Physics, University of Wisconsin, Madison, WI; Mayo Clinic, Jacksonville, FL; University of Virginia Medical Center, Charlottesville, VA; National Surgical Adjuvant Breast and Bowel Project and SCCC-CCOP, Goldboro, NC; Arizona Oncology Services Foundation, Phoenix, AZ; Thomas Jefferson University Hospital, Philadelphia, PA; University of Maryland, Baltimore, MD

Abstract Disclosures


Abstract:

Background: RTOG 0825 evaluated the addition of BEV to standard CRT in the treatment of GBM and included molecular stratification that assessed the degree of mesenchymal (MES) gene enrichment. We investigated the ability of the MES signature to predict response to BEV. Methods: Sufficient FFPE tissue for molecular analysis was available for 650 registered, eligible patients. TaqMan PCR was performed prospectively using the molecular stratifier on all patients and an expanded 43 member MES set on 234 cases. A subset of specimens was subjected to whole genome expression profiling (GEP). Predictive models were evaluated for their ability to predict survival (overall, OS, and progression-free, PFS) in the training cohort of the BEV arm after adjusting for prognostic factors and treatment arm. Unsupervised clustering of GEP data was used to identify molecular subsets and gene set enrichment analysis (GSEA) performed to evaluate for MES enrichment. Results: We observed a significant association between increasing MES signature and worse PFS and OS in the BEV arm (p=0.036 and p=0.032, respectively). Based on the association between high MES expression and poor outcome in the BEV arm, we sought to optimize a predictor using an expanded set of MES genes. Unbiased gene selection from a total of 43 genes followed by radial basis machine modeling identified a 10-gene predictor of outcome in the BEV arm (p<0.001/HR 4.04 for OS and p<0.001/HR 2.21 for PFS). To further support the association of MES enrichment and poor outcome in the BEV arm, we performed GEP. Unsupervised clustering identified a subtype of tumors with MES enrichment associated with the 10-gene predictor survival probability (p=0.0124, t-test). Ongoing studies will determine the extent to which this represents a predictive marker for BEV. Conclusions: We developed a 10-gene predictor specific to BEV treatment and suitable for FFPE that may serve to identify subsets of patients with newly diagnosed GBM who benefit from BEV. Supported by RTOG grant U10 CA21661, CCOP grant U10 CA37422, and Brain SPORE P50 CA127001 from the NCI and Genentech. Clinical trial information: NCT00884741.

 

  Other Abstracts in this Sub-Category:

 

1. RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).

Meeting: 2013 ASCO Annual Meeting Abstract No: 1 First Author: M. R. Gilbert
Category: Central Nervous System Tumors - CNS Tumors

 

2. Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-nonmethylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.

Meeting: 2013 ASCO Annual Meeting Abstract No: LBA2000 First Author: U. Herrlinger
Category: Central Nervous System Tumors - CNS Tumors

 

3. A randomized phase II study of bevacizumab versus bevacizumab plus lomustine versus lomustine single agent in recurrent glioblastoma: The Dutch BELOB study.

Meeting: 2013 ASCO Annual Meeting Abstract No: 2001 First Author: W. Taal
Category: Central Nervous System Tumors - CNS Tumors

 

More...